InterCure (NASDAQ:INCR) Shares Down 6.6% – Here’s What Happened

Shares of InterCure Ltd. (NASDAQ:INCR) dropped 6.6% during mid-day trading on Tuesday . The stock traded as low as $0.9895 and last traded at $0.99. Approximately 537,181 shares were traded during trading, an increase of 833% from the average daily volume of 57,585 shares. The stock had previously closed at $1.06.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, InterCure currently has a consensus rating of “Sell”.

InterCure Trading Down 8.4%

The firm has a 50 day simple moving average of $1.32 and a 200 day simple moving average of $1.47. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.09 and a current ratio of 1.85.

InterCure (NASDAQ:INCR) last announced its quarterly earnings results on Wednesday, October 8th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $19.25 million during the quarter.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.